Placeholder Banner

BIO Sends Letter to Congressional Leaders on Need to Repeal Harmful R&D Amortization Provision

June 15, 2022

The Biotechnology Innovation Organization (BIO), BIO members and State affiliates urge immediate legislative action to repeal the harmful R&D amortization provision that went into effect earlier this year. The 2017 Tax Cuts and Jobs Act (TCJA) changed the longstanding deduction for R&D expenditures to a mandatory five-year amortization for domestic R&D and fifteen-year amortization for foreign R&D, with the effective date delayed until 2022. As has been noted by companies and industries across the economy, the R&D amortization provision will have a negative impact on American innovation and high-paying R&D jobs. For the biotechnology industry specifically, it will divert much-needed funds away from small R&D-intensive companies, potentially doing long-term damage to the development of the future treatments and ultimately limiting the pipeline of treatments and products that patients and consumers are relying on our industry to develop; technologies that help heal, fuel, and feed the world.


For this reason, legislation should be enacted to restore the expensing of R&D expenditures retroactive to January 1, 2022.

Download Full Comments Below
BIO%20Section%20174%20Letter_Final.pdf
Discover More
On Monday, June 13th, BIO submitted comments in response to a recently published FDA draft guidance providing recommendations to sponsors on developing a Race and Ethnicity Diversity Plan to enroll adequate numbers of participants in clinical trials…
The Biotechnology Innovation Organization (BIO) is pleased to submit a statement for the record to the to the United States House of Representatives Select Committee on the Climate Crisis hearing entitled, “Climate Smart From Farm to Fork: Building…
We are writing on behalf of the Biotechnology Innovation Organization (BIO) to provide comments on the Federal Trade Commission’s (FTC’s or the Commission’s) Solicitation for Public Comments on the Business Practices of Pharmacy Benefit Managers and…